CIBC reiterated their market perform rating on shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in a research report report published on Thursday, August 3rd.
A number of other equities analysts also recently commented on the company. UBS AG downgraded Teva Pharmaceutical Industries Limited from an outperform rating to a market perform rating in a research report on Thursday, August 3rd. Credit Suisse Group set a $39.00 price target on Teva Pharmaceutical Industries Limited and gave the company a buy rating in a report on Thursday, August 3rd. Oppenheimer Holdings, Inc. downgraded Teva Pharmaceutical Industries Limited from an outperform rating to a market perform rating and set a $41.00 price objective for the company. in a report on Thursday, August 3rd. Mizuho reissued a hold rating and issued a $30.00 price objective on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday, August 2nd. Finally, Jefferies Group LLC reissued a hold rating on shares of Teva Pharmaceutical Industries Limited in a report on Tuesday, July 25th. Three research analysts have rated the stock with a sell rating, twenty have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Teva Pharmaceutical Industries Limited has an average rating of Hold and an average price target of $36.73.
Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) traded down 2.23% during midday trading on Thursday, hitting $17.10. 12,988,997 shares of the stock traded hands. Teva Pharmaceutical Industries Limited has a 12-month low of $16.81 and a 12-month high of $53.96. The stock’s market cap is $17.37 billion. The company’s 50 day moving average price is $28.36 and its 200-day moving average price is $31.20.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. During the same period in the prior year, the firm posted $1.25 earnings per share. The business’s quarterly revenue was up 12.9% compared to the same quarter last year. On average, equities research analysts expect that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 14th. Investors of record on Tuesday, August 29th will be given a dividend of $0.085 per share. The ex-dividend date of this dividend is Friday, August 25th. This represents a $0.34 dividend on an annualized basis and a yield of 1.99%. Teva Pharmaceutical Industries Limited’s dividend payout ratio is currently -18.95%.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TEVA. SOL Capital Management CO raised its position in Teva Pharmaceutical Industries Limited by 10.1% in the first quarter. SOL Capital Management CO now owns 61,693 shares of the company’s stock worth $1,980,000 after buying an additional 5,670 shares in the last quarter. Kempner Capital Management Inc. raised its position in shares of Teva Pharmaceutical Industries Limited by 18.9% in the first quarter. Kempner Capital Management Inc. now owns 200,050 shares of the company’s stock worth $6,420,000 after buying an additional 31,860 shares during the period. National Pension Service raised its position in shares of Teva Pharmaceutical Industries Limited by 8.6% in the first quarter. National Pension Service now owns 732,038 shares of the company’s stock worth $23,945,000 after buying an additional 57,726 shares during the period. Country Club Trust Company n.a. raised its position in shares of Teva Pharmaceutical Industries Limited by 5.7% in the first quarter. Country Club Trust Company n.a. now owns 164,839 shares of the company’s stock worth $5,290,000 after buying an additional 8,870 shares during the period. Finally, Berson & Corrado Investment Advisors LLC acquired a new position in shares of Teva Pharmaceutical Industries Limited during the first quarter worth about $1,072,000. Institutional investors and hedge funds own 56.04% of the company’s stock.
Teva Pharmaceutical Industries Limited Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.
